References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin 2015; 65: 5-29. PMID: 25559415; http://dx.doi.org/10.3322/caac.21254
- Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12):907-13. PMID: 8120958; http://dx.doi.org/10.1001/jama.1994.03510360033032
- Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66(7):3381-5. PMID: 16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19):1803-13. PMID: 26406148; http://dx.doi.org/10.1056/NEJMoa1510665